Silence Therapeutics Plc, which is developing RNAi-generated therapies, has appointed Thomas Christély as chief executive, following the resignation of Phil Haworth some months ago.
Mr Christély was the chief operating officer and the chief executive of Silence’s German company. In his 10 years with the group, Mr Christély was instrumental in the merger of the British and German companies that became Silence Therapeutics. He also helped Silence Therapeutics obtain a listing in London. He will be based in Berlin.
Copyright 2011 Evernow Publishing Ltd